MarketCap
Facebook
X
Telegram
Apellis Pharmaceuticals Operating Cash Flow | APLS
Annual Operating Cash Flow Apellis Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 45.3 M | -87.9 M | -595 M | -514 M | -563 M | -160 M | -211 M | -131 M | -46.6 M | -26 M | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 45.3 M | -595 M | -229 M |
Quarterly Operating Cash Flow Apellis Pharmaceuticals
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -61 M | 59.5 M | - | -53.4 M | - | - | - | -133 M | - | - | - | -178 M | - | -373 M | -219 M | -112 M | - | -451 M | -282 M | -153 M | - | -302 M | -203 M | -108 M | - | -129 M | -75.5 M | -35.6 M | - | -86.8 M | -53.6 M | -22.9 M | - | -31.1 M | -19.9 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 59.5 M | -451 M | -137 M |
Operating Cash Flow of other stocks in the Biotechnology industry
| Issuer | Operating Cash Flow | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Athira Pharma
ATHA
|
-45.7 M | - | - | $ 269 M |  USA |
 |
Avenue Therapeutics
ATXI
|
-1.83 M | - | -52.27 % | $ 4.45 M | USA |
 |
AVROBIO
AVRO
|
-60.1 M | - | 1083.1 % | $ 745 M | USA |
 |
AstraZeneca PLC
AZN
|
14.6 B | - | - | $ 96.9 B |  Britain |
 |
Brainstorm Cell Therapeutics
BCLI
|
-6.98 M | - | -2.5 % | $ 5.88 M | USA |
 |
BeiGene, Ltd.
BGNE
|
1.13 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Bio-Path Holdings
BPTH
|
-10.6 M | - | - | $ 100 K | USA |
 |
Cara Therapeutics
CARA
|
-23.5 M | - | -3.03 % | $ 260 M | USA |
 |
ChromaDex Corporation
CDXC
|
13.5 M | - | -0.88 % | $ 598 M | USA |
 |
Caladrius Biosciences
CLBS
|
-15.9 M | - | -16.75 % | $ 25.8 M | USA |
 |
Cyclacel Pharmaceuticals
CYCC
|
-4.77 M | - | -5.98 % | $ 34.1 M | USA |
 |
Cyclacel Pharmaceuticals
CYCCP
|
-4.77 M | - | -4.36 % | $ 27 M | USA |
 |
Diffusion Pharmaceuticals
DFFN
|
-23.4 M | - | 11.68 % | $ 8.97 M | USA |
 |
Eloxx Pharmaceuticals
ELOX
|
-5.45 M | - | -5.68 % | $ 8.28 M | USA |
 |
Enochian Biosciences
ENOB
|
-5.29 M | - | - | $ 40.5 M | USA |
 |
Esperion Therapeutics
ESPR
|
-13.1 M | - | - | $ 661 M | USA |
 |
Evofem Biosciences
EVFM
|
-1.99 M | - | 7.55 % | $ 38.1 M | USA |
 |
Eyenovia
EYEN
|
-14.8 M | - | 49.81 % | $ 13.2 M | USA |
 |
FibroGen
FGEN
|
-4.77 M | - | - | $ 889 M | USA |
 |
Homology Medicines
FIXX
|
-33.5 M | - | 0.77 % | $ 53.4 M | USA |
 |
Amicus Therapeutics
FOLD
|
33.1 M | - | - | $ 4.47 B | USA |
 |
Frequency Therapeutics
FREQ
|
-78.6 M | - | - | $ 528 M | USA |
|
Galecto
GLTO
|
-6.73 M | - | - | $ 762 M |  Danmark |
 |
GlycoMimetics
GLYC
|
-71.5 M | - | 9357.83 % | $ 1.01 B | USA |
 |
Graybug Vision
GRAY
|
-21.2 M | - | -11.23 % | $ 9.65 M | USA |
|
Galera Therapeutics
GRTX
|
-6.05 M | - | -32.59 % | $ 7.61 M | USA |
 |
Happiness Biotech Group Limited
HAPP
|
-1.4 M | - | 1.35 % | $ 17.8 M |  China |
 |
Hepion Pharmaceuticals
HEPA
|
-3.27 M | - | -18.79 % | $ 39.3 K | USA |
 |
Hoth Therapeutics
HOTH
|
-9.8 M | - | - | $ 18.8 M | USA |
 |
IMARA
IMRA
|
-70.3 M | - | 15.96 % | $ 663 M | USA |
 |
KalVista Pharmaceuticals
KALV
|
-81.6 M | - | - | $ 1.45 B | Britain |
 |
KemPharm
KMPH
|
-1.6 M | - | -0.34 % | $ 200 M | USA |
 |
Kezar Life Sciences
KZR
|
-51.8 M | - | - | $ 53.3 M | USA |
 |
Lixte Biotechnology Holdings
LIXT
|
-3.07 M | - | - | $ 63.4 M | USA |
 |
Magenta Therapeutics
MGTA
|
-129 M | - | -7.74 % | $ 41.6 M | USA |
 |
NovaBay Pharmaceuticals
NBY
|
-8.43 M | - | - | $ 11.3 M | USA |
 |
NeuroBo Pharmaceuticals
NRBO
|
-15.7 M | - | 0.43 % | $ 12 M | USA |
 |
OncoCyte Corporation
OCX
|
-22.2 M | - | 17.22 % | $ 355 K | USA |
 |
Onconova Therapeutics
ONTX
|
-18.2 M | - | -0.47 % | $ 21 M | USA |
 |
Opthea Limited
OPT
|
-159 M | - | - | $ 1.2 B |  Australia |
|
BiomX
PHGE
|
-26.4 M | $ 1.85 | 14.2 % | $ 3.02 M |  Israel |
 |
Pieris Pharmaceuticals
PIRS
|
-25 M | - | -15.58 % | $ 1.22 B |  Germany |
 |
Plus Therapeutics
PSTV
|
-20.8 M | - | - | $ 301 M | USA |
 |
Pluristem Therapeutics
PSTI
|
-19.6 M | - | -1.9 % | $ 33.3 M | Israel |
 |
Qualigen Therapeutics
QLGN
|
-6.95 M | - | 5.59 % | $ 1.16 M | USA |
|
Qilian International Holding Group Limited
QLI
|
-2.37 M | - | -6.08 % | $ 184 M | China |
 |
Cassava Sciences
SAVA
|
-32.3 M | - | - | $ 110 M | USA |
 |
Selecta Biosciences
SELB
|
-73.9 M | - | -8.69 % | $ 126 M | USA |
 |
Sangamo Therapeutics
SGMO
|
-97.2 M | - | - | $ 50.4 M | USA |